Skip to content

OMDA OMDA Cash & Equivalents

Cash & Equivalents at other companies

Teladoc Health logo
Teladoc HealthTDOC
$750.74M-37.1%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$118.12M+211%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$179.33M+235%
AdaptHealth logo
AdaptHealthAHCO
$47.96M-10.6%
Eli Lilly logo
Eli LillyLLY
$5.28B+70.8%
Insulet logo
InsuletPODD

Other financials

Income statement

See full
Revenue$78.0M+42.0%
Gross profit$48.7M+52.6%
Operating income-$4.8M+43.1%
Net income-$3.0M+68.6%
EPS (diluted)-$0.05+95.7%

Balance sheet

See full
Total debt$30.0M
Total equity$234.1M+160%
Total assets$302.8M

Cash flow

See full
Operating cash flow-$11.8M+26.6%
CapEx$78.0K-75.2%
Free cash flow-$11.9M+27.5%

Valuation

See full
Market cap$1.11B+23.8%
P/S3.9×-0.4×

Profitability

See full
Gross margin66.3%+4.4pp
Operating margin-9.6%-4.0pp
Net margin-11.3%-4.6pp
FCF margin-40.8%

Returns & leverage

See full
Return on equity26.8%
Debt / equity0.1×
Current ratio3.9×

Where this comes from

Reported directly by OMDA in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: OMDA’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about OMDA's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OMDA's cash & equivalents?
OMDA (OMDA) reported cash & equivalents of $211.77M in Q1 2026.
How has OMDA's cash & equivalents changed year-over-year?
OMDA's cash & equivalents increased by 256.5% year-over-year, from $59.4M to $211.77M.
What is the long-term trend for OMDA's cash & equivalents?
Over 2 years (2023 to 2025), OMDA's cash & equivalents has grown at a 38.6% compound annual growth rate (CAGR), from $115.64M to $222.04M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.